GLP-1 Manufacturing at Scale: How Lilly and Novo Are Meeting Demand in 2026

Eli Lilly investing $23B+ in manufacturing. Novo Nordisk expanding globally. How GLP-1 production scale-up is resolving shortages and reshaping pharmaceutical supply chains.

The GLP-1 supply crisis of 2023-2024 exposed a fundamental challenge: pharmaceutical manufacturing infrastructure wasn't built for a drug class that would eventually serve 10-20% of the adult population. Both Eli Lilly and Novo Nordisk have responded with manufacturing investments measured in tens of billions of dollars.

Eli Lilly: $23 Billion+ Manufacturing Commitment

Lilly has announced over $23 billion in manufacturing investments since 2023, including new facilities in Indiana, North Carolina, and Ireland specifically for injectable drug product capacity. The expansions target both tirzepatide (Mounjaro/Zepbound) and pipeline compounds (retatrutide, bimagrumab). Fill-finish capacity — the bottleneck for injectable medications — has been a particular focus.

Novo Nordisk: Global Expansion

Novo has invested heavily in Denmark-based production (Hillerød and Kalundborg sites) and announced partnerships for additional capacity in the US and Europe. The company's API production for semaglutide relies on complex fermentation and purification processes that require 12-18 months of lead time from facility construction to first batch.

The Shortage Resolution Timeline

As of mid-2026, the semaglutide shortage has largely resolved in the US market. Tirzepatide supply has stabilized. However:

• Specific dose strengths may still experience intermittent shortages
• International markets, particularly developing countries, continue to face limited access
• The FDA's drug shortage list — which affects the legality of compounding — is updated based on current supply status

Implications for the Compounded Market

As brand-name supply normalizes, the legal basis for compounding under shortage provisions narrows. However, 503A pharmacies compounding under individual prescription (with meaningful differences from the brand-name product) and 503B outsourcing facilities operating within FDA regulations continue to provide compounded versions. The price differential — $99-200/month compounded vs. $1,000+ brand-name — ensures continued demand regardless of shortage status.

The Oral Manufacturing Challenge

Oral GLP-1 formulations (semaglutide 25mg tablets, orforglipron) present different manufacturing challenges than injectables: high-volume solid-dose production rather than sterile fill-finish. Both Lilly and Novo have separate manufacturing programs for oral formulations, which may eventually reduce per-unit costs as oral becomes the dominant delivery format.